This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
About us
TraffikGene is a business initiative originating at Universidad de Santiago de Compostela (Spain) focused on the development of a non-viral gene delivery platform based on peptide amphiphiles
Vision
To leverage our proprietary technology platform allowing nucleic acid therapeutics to be delivered efficiently and safely to its site of action.
Mission
To allow the next generation of nucleic acid therapeutics to reach the market faster and with better risk-benefit profiles, reaching patients in need.
Technology
Overcoming current gene delivery challenges
We have developed a novel peptide-based gene delivery platform featuring:
-Accelerated vehicle discovery: Structure activity predictability
–Single vehicle formulation
–Targeting beyond the liver
-Broad cargo versatility
-Patent pending: well differentiated from LNP approaches
High-throughput carrier customization enables optimization for desired delivery characteristics
Validated in vivo data
mRNA admin. route versatility
Tuneable mRNA targeting beyond the liver
Leadership Team
Funding & Support
Funded under Horizon Europe framework – EIC Transition Challenge project TraffikGene-Tx (Ref: 101113110 — HORIZON-EIC-2022-TRANSITION-01) during the period 06/2023 – 05/2026.
